UBX — Unity Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $15.73m
- -$1.20m
Annual cashflow statement for Unity Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -93.8 | -60.7 | -44.5 | -39.9 | -26 |
| Depreciation | |||||
| Non-Cash Items | 16.6 | 13.4 | -9.1 | 5.98 | 0.867 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.55 | -0.631 | -1.02 | -4.39 | 3.39 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -78.3 | -45.1 | -52.4 | -37.1 | -20.9 |
| Capital Expenditures | -0.646 | -0.195 | -0.096 | -0.011 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -4.56 | 39.5 | -24.4 | 60.5 | 8.56 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.21 | 39.3 | -24.5 | 60.5 | 8.56 |
| Financing Cash Flow Items | 0 | — | -1.97 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 63.9 | 20.8 | 56.2 | -16.3 | 0.077 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -19.7 | 15.1 | -20.7 | 7.07 | -12.2 |